MRNA therapy takes on Hard-to-Treat multiple myeloma
NCT ID NCT07116616
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 23 times
Summary
This study tests a new drug called mRNA-2808 in people with multiple myeloma that has returned or not responded to standard treatments. The drug is given through a vein and aims to control the cancer. The trial will check for side effects and measure how well the drug works. About 166 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
-
Mass General Brigham
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer Center
NOT_YET_RECRUITINGNew York, New York, 10065, United States
-
Penn Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
The Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Tisch Cancer Institute at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
UCSF
NOT_YET_RECRUITINGSan Francisco, California, 94143, United States
-
University of Alabama at Birmingham Hospital
RECRUITINGBirmingham, Alabama, 35233, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-2808
What this could lead to
If successful, this could provide a new treatment option for people with multiple myeloma that has not responded to other therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the treatment may not prove effective or safe. Side effects are unknown and could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.